Alzheimer’s Disease Biomarkers Market | USD 2,087.44 Million by 2034
The global Alzheimer’s disease biomarkers market size accounted for USD 1,022.29 million in 2024 and is predicted to increase from USD 1,097.93 million in 2025 to approximately USD 2,087.44 million by 2034, expanding at a CAGR of 7.4% from 2025 to 2034. The demand for early detection and diagnosis of Alzheimer’s disease is driving the Alzheimer’s disease biomarkers market. The increased use of biomarkers in the development of personalized medicines & treatments is fueling the market expansion.
| Report Coverage | Details |
| Market Size in 2025 | USD 1,097.93 Million |
| Market Size by 2034 | USD 2,087.44 Million |
| Growth Rate From 2025 to 2034 | CAGR of 7.4% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | By Type of Biomarkers, By Detection Technique, By End-user, By Regional Insights |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Thermo Fisher Scientific, Inc. Enzo Life Sciences, Inc. AnaSpec, Inc. QIAGEN, 23andMe, Inc. Quanterix, Merck KGaA, Cell Signaling Technology, Inc. Fujirebio, Imagilys, NanoSomiX, C₂N Diagnostics, Quest Diagnostics |
The Alzheimer’s disease biomarkers market is witnessing significant growth, driven by the increased prevalence of Alzheimer's disease, particularly in the aging population, and developments of non-invasive treatments and tools. Biomarkers are used in the early detection and diagnosis of Alzheimer’s disease. Developments in neuroimaging techniques and biomarker discovery are fueling the market growth. Researchers are focusing on developing disease-modifying treatments for Alzheimer's, contributing to the increasing need for blood biomarkers.
The utilization of biomarkers has increased in drug development. Biomarkers are being used in the development of Biomarkers are being used in the development of tests for early detection and diagnosis of Alzheimer’s disease. Increase the need for personalized treatment approaches based on individual patients' genetic profiles, driving the need for biomarkers in development. Biomarkers are offering cost-effective approaches in clinical trials by identifying potential patients and reducing extreme patient needs. Job development and clinical trials are significantly using biomarkers for the detection of targets, monitoring disease progression, and development of effective experimental treatments.
Key Trends Boosting the Alzheimer’s Disease Biomarkers Market
Demand for Personalized Treatments has the Potential to Boost the Alzheimer’s Disease Biomarkers Market Expansion
The growing prevalence of Alzheimer’s disease is driving demand for personalized treatments. Development of personalized treatments based on biomarker profiles to improve patient outcomes, driving significant growth. Advancements in technologies like next-generation sequencing and mass spectrometry enable the development of more reliable, effective, and accurate biomarkers for Alzheimer’s disease. Biomarkers help with early detection and enable plans for accurate treatments based on individual patient genetic profiles. The increased need for personalized treatments is driving demands for biomarkers to enhance the accuracy of diagnosis and disease monitoring.
High-Cost Hampers Alzheimer's Disease Biomarkers Market Growth
The high cost associated with Alzheimer’s disease biomarkers is the major restraint on market growth. Innovations and developments of Alzheimer's disease biomarkers require significant investments in the R&D sector. The cost associated with equipment and materials further causes challenges. Developments of novel biomarkers can hamper pharmaceutical companies' margin profiles. Additionally, the biomarkers often require complex and specialized testing comma which further contributes often require complex and specialized testing, which can be expensive. High costs associated with the latest diagnostic tools and new therapies like amyloid PET imaging and CSF testing cause a burden to the patients.
The CSF Biomarkers segment dominated the market in 2024. CSF biomarkers have established a clinical utility in the diagnosis and monitoring of Alzheimer's disease. CSF biomarkers are widely used in the prediction and detection of Alzheimer’s disease progression. The high sensitivity and specificity make them ideal for the detection of Alzheimer’s disease.
However, the blood biomarkers segment is expected to lead the market in the forecast period. Blood biomarkers are non-invasive, cost-effective, and highly scalable in Alzheimer's disease (AD) diagnosis and research. Blood samples are easy to collect and analyze; mixed blood biomarkers are attractive alternatives for the diagnosis and monitoring of Alzheimer’s disease.
The immunoassays segment generated the biggest market revenue share in 2024. The segment growth is accounted for by its wide availability and adoption. Immunoassay is a simple and cost-effective detection method, which can be developed and applied to biological samples. Immunoassays are highly sensitive for the detection of Alzheimer’s disease biomarkers.
The molecular diagnostics segment is projected to witness significant growth in the forecast period. Molecular diagnostic detection techniques are non-invasive and highly accurate. This technique enables early detection of Alzheimer's disease. Ongoing research on disease-modifying therapies contributes to the adoption of molecular diagnostic techniques.
The hospitals & clinics segment dominated the market due to the high patient population. Hospitals and clinics are well-equipped with state-of-the-art diagnostic facilities and specialized care for Alzheimer’s disease diagnosis and treatment. Government funding for healthcare facilities is further contributing to and increasing patient volume in hospitals and clinics.
The Diagnostic Laboratories segment is the second largest segment leading the market. Diagnostic laboratories provide centralized testing for Alzheimer's disease biomarkers. The increased need for early and accurate diagnosis is driving the adoption of biomarkers in diagnostic laboratories. Download diagnostic laboratories offer cost-effective testing options for Alzheimer’s disease biomarkers, making them popular among patients.
North America Alzheimer’s Disease Biomarkers Market Trends
North America dominates the global Alzheimer’s disease biomarkers market due to factors like the high prevalence of Alzheimer's disease, advanced healthcare infrastructure, a favorable regulatory ecosystem, and high investment in the research and development sector. North America has a favorable regulatory environment for development as well as approval for noble biomarkers and treatment solutions, contributing to advancing Alzheimer’s disease treatments and diagnostics.
The Aging Population is Contributing to the U.S. Alzheimer's Disease Biomarkers Market Growth
The United States leads the regional market due to the high prevalence of Alzheimer's disease in the country. Major healthcare spending and the presence of key vendors are contributing to the market expansion. The United States has a high number of aging populations, increasing demand for Alzheimer’s disease treatment and diagnostics in the country. The market is further attributed to witnessing growth due to high investment in research and development. Ongoing innovations and developments of Alzheimer's disease biomarkers for aging populations boost the market growth.
In July 2024, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Kisunla™, an Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), including people with mild cognitive impairment (MCI) and mild dementia stage of AD, with confirmed amyloid pathology.
Asia Pacific Alzheimer’s Disease Biomarkers Market Trends
Asia Pacific is expected to witness significant growth in focus due to the increased prevalence of Alzheimer’s disease, particularly in the aging population. Asia Pacific has a high adoption rate of biomarkers for Alzheimer’s disease diagnostics. Advanced healthcare infrastructure and government support and funding for the research and development sector are crucial factors. The demand for early detection and diagnostics has increased in the region.
Countries like Japan, Australia, India, and South Korea dominate the Alzheimer’s disease market. The growth is driven by the increased adoption of biomarkers and the high prevalence of Alzheimer’s disease in the aging population. Government and regulatory initiatives and investments in research and development and pharmaceutical manufacturing companies contribute to market expansion.
In September 2024, "Make in India" initiatives encouraging the development and manufacturing of in vitro diagnostic tools for early detection of critical diseases such as Alzheimer’s, cancer, and gastrointestinal disorders were permitted by the Drugs Controller General of India (DCGI) for manufacturing in Kochi, Kerala.
By Type of Biomarkers
By Detection Technique
By End-user
By Geography
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers